Loss of heterozygosity of the TP53 tumor suppressor gene and detection of point mutations by the non-isotopic RNase cleavage assay in prostate cancer

Cancer Genetics and Cytogenetics

Volumn 108, Issue 1, 1999, Pages 42-47

  Macera, M J ^a   Godec, C J ^a   Sharma, N ^a   Verma, R S ^a  

^a LONG ISLAND COLLEGE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBONUCLEASE;

ARTICLE; CLINICAL ARTICLE; DNA SEQUENCE; GENETIC POLYMORPHISM; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SURVIVAL TIME; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; BIOPSY; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; DNA; GENES, P53; HUMANS; INTRONS; LOSS OF HETEROZYGOSITY; MALE; MOLECULAR SEQUENCE DATA; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RIBONUCLEASES; TUMOR CELLS, CULTURED;

EID: 0032910897     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(98)00109-5     Document Type: Article

References (31)

1. Boring C.C., Squires T.S., Montgomery S. Cancer Statistics 1994. CA Cancer J Clin. 44:1994;7-26.
2. Coffey D.S. Prostate cancer. an overview of an increasing dilemma Cancer. 71:1993;880-886.
3. Cannon-Albright L., Eeles R. Progress in prostate cancer. Nat Genet. 9:1995;336-338.
4. Brookstein R., MacGrogan D., Hilsenbeck S.G., Sharkey F., Allred D.C. P53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 53:1993;3369-3373.
5. Alcaraz A., Takahashi S., Brown J.A., Herath J.F., Bergstralh E.J., Larson-Keller J.J., Lieber M.M., Jenins R.B. Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. Cancer Res. 54:1994;3998-4002.
6. Rinker-Schadffer C.W., Hawkins A.L., Ru N., Dong J., Stocia G., Griffin C.A. Differential suppression of mammary and prostate cancer metastasis by human chromosome 17 and 11. Cancer Res. 54:1994;6249-6256.
7. Lowe S.W., Bodis S., McCarthy A., Remington L.K., Ruley H.E., Fisher D.E., Housman D.E., Jacks T. p53 status and the efficiency of cancer therapy in vivo. Science. 266:1994;807-810.
8. Van Den Berg C., Guan X.-Y., Von Hoff D., Jenkins R., Bittner M., Griffen C., Kalliohiemi O., Visakorpi T., McGill J., Hearth J., Epstein J., Sarosdiy M., Meitzer P. DNA sequence amplification in human prostate cancer identified by chromosome microdissection of potential prognostic implication. Clin Cancer Res. 1:1995;11-18.
9. Isaacs W.B., Bova G.S., Morton R.A., Bussemakers M.J.G., Brooks J.D., Ewing C.M. Molecular biology of prostate cancer. Semin Oncol. 21:1994;1-18.
10. Macoska J.A., Trubus T.M., Sakr W.A., Wolf M.C., Benson P.O., Powell I.J., Pontes J.E. Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer. Cancer Res. 54:1994;3824-3832.
11. Isaacs W.B., Carter B.S., Ewing C.M. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res. 51:1991;4716-4720.
12. Olinder JD (1994): The role of p53 in cancer development. Sci Am Sept/Oct:16-25.
13. Fung C.Y., Fisher D.E. p53. From molecular mechanisms to prognosis in cancer J Clin Oncol. 13:1995;808-811.
14. Kuerbitz S., Plunkett B., Walsh W., Kasten M.B. Wildtype p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA. 89:1992;7491-7495.
15. Levine A.J., Momand J., Finlay C.A. The p53 tumor suppressor gene. Nature. 351:1991;453-456.
16. Nigro J.M., Baker S.J., Preisinger A.C., Jessup J.M., Hostetter R., Cleary K., Bigner S.H., Davidson N., Baylin S., Devilee P., Glover T., Collins F.S., Weston A., Modali R., Harris C.C., Vogelstein B. Mutations in the p53 gene occur in diverse human tumor types. Nature. 342:1989;705-708.
17. Goh H.S., Yao J., Smith D. P53 point mutations and survival in colorectal cancer patients. Cancer Res. 55:1995;5217-5221.
18. Brooks J.D., Bova G.S., Ewing C.M., Piantadosi S., Carter B.S., Robinson J.C., Epstein J.I., Isaacs W.B. An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res. 56:1996;3814-3822.
19. Chi S.-G., deVere White R.W., Meyers F.J., Siders D.B., Lee F., Cumerlock P.H. p53 in prostate cancer. frequent expressed transition mutations J Natl Cancer Inst. 86:1994;926-933.
20. Effert P., Neubauer A., Walther P.J., Liu E.T. Alterations of the p53 gene are associated with the progression of a human prostate carcinoma. J Urol. 147:1992;789-793.
21. Navone N.M., Troncoso P., Pister L.L., Goodrow T.L., Palmer J.L., Nichols W.W., Von Echenbach A.C., Conti C.J. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst. 85:1993;1657-1669.
22. Trapman J., Sleddens H.F.B.M., van der Weiden M.M., Dinjens W.N.M., Konig J.J., Shroder F.H., Faber P.W., Bosman F.T. Loss of heterozygosity of chromosome 8 micro satellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. Cancer Res. 54:1994;6061-6064.
23. Voeller H.J., Sugars L.Y., Pretlow T.L., Gelmann E.P. p53 oncogene mutations in human prostate cancer specimens. J Urol. 151:1994;492-495.
24. Hamelin R., Laurent-Puig P., Olschwang S., Jego N., Asselain B., Remivikos Y., Girodet J., Salmon R.J., Thomasa G. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology. 106:1994;42-48.
25. Goldrick M.M., Kimball G.R., Liu Q., Martin L.A., Sommer S.S., Tseng J.Y.-H. NIRCA™ a rapid robust method for screening for unknown point mutations Biotechniques. 21:1996;106-112.
26. Konig J.J., Teubel W., Kamst E., Romijin J.C., Schroder F.H., Hagemeijer A. Cytogenetic analysis of 39 prostate carcinomas and evaluation of short term tissue culture techniques. Cancer Genet Cytogenet. 101:1998;116-122.
27. Hollestein M., Sidransky D., Vogelstein M., Harris C.C. P53 mutation in human cancers. Science. 253:1991;49-53.
28. Greenblatt M.S., Bennet W.P., Hollestein M., Harris C.C. Mutations in the p53 tumor suppressor gene. clues to cancer etiology and molecular pathogenesis Cancer Res. 54:1994;4855-4878.
29. Levine A.J., Perry M.E., Chang A., Silver A., Dittmer D., Wu M., Welsh D. The role of the p53 tumor suppressor gene in tumorigenesis. The 1993 Walter Hubert Lecture. Br J Cancer. 69:1994;409-416.
30. Knudson A.G. Jr. Hereditary cancers of man. Cancer Invest. 1:1983;187-190.
31. Kleihues P., Schauble B., zur Hausen A., Esteve J., Ohgaki H. Tumors associated with p53 germline mutations, a synopsis of 91 families. Am J Pathol. 150:1997;1-9.